Onmez, AttilaGokosmanoglu, FeyziBaycelebi, GulsahArikan, Ali Ahmet2021-12-012021-12-0120211368-55381473-0790https://doi.org/10.1080/13685538.2020.1758657https://hdl.handle.net/20.500.12684/10875Aim: Sodium-glucose cotransporter 2 inhibitors have been shown to reduce the risk of cardiovascular disease in type 2 diabetes (T2DM) patients. The purpose of this study was to evaluate cardiovascular disease risk indirectly through Doppler ultrasonography (USG) of carotid artery vascular markers in T2DM patients using dapagliflozin. Methods: One hundred forty-five patients presenting to our clinic between March 2016 and June 2018 and diagnosed with T2DM were included in the study. These were divided into two groups - a dapagliflozin group of 85 patients and a 60-member non-dapagliflozin control group. Common carotid artery end-diastolic velocity (EDV), peak systolic velocity (PSV), and resistive index (RI) parameters were evaluated using Doppler USG in both groups. Results: The mean duration of follow-up was 2.2 +/- 0.4 years. Mean ages were 45 +/- 14 years in the dapagliflozin group and 42 +/- 15 in the control group. Mean HbA1c was 7.4 +/- 1.6 in the dapagliflozin group and 7.3 +/- 2.1 in the control group. Common carotid artery, PSV, and EDV parameters were higher (p = .012/p = .036), while RI was lower (p < .001), in the dapagliflozin group than in the control group. Conclusion: Vascular resistance was lower in the group using dapagliflozin for diabetes management.en10.1080/13685538.2020.1758657info:eu-repo/semantics/openAccessDapagliflozinend-diastolic velocityresistive indexcarotid Dopplertype 2 diabetesEndothelial FunctionMetabolic SyndromeArteryAtherosclerosisTestosteroneParametersInhibitorsImpactIndexArticle23512461250323427182-s2.0-85084268581WOS:000532018500001Q2Q1